Zoledronic acid monohydrate
Based on 26 publication(s) in Google Scholar
Zoledronic acid monohydrate (Zoledronate monohydrate) is a third-generation bisphosphonate (BP), with potent anti-resorptive activity. Zoledronic acid monohydrate inhibits the differentiation and apoptosis of osteoclasts. Zoledronic acid monohydrate also has anti-cancer effects.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 99.58%
- CAS No.: 165800-06-6
- 화학식: C5H12N2O8P2
- 분자량:290.10
-
보관:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
용액&용해도
- 순도&문서
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Zoledronic acid monohydrate
More- Natl Sci Rev. 2025 Jun 27;12(8):nwaf256. [Abstract]
- Nat Commun. 2024 Mar 21;15(1):2529. [Abstract]
- ACS Nano. 2023 Jul 25;17(14):13917-13937. [Abstract]
- Gut Microbes. 2023 Dec;15(2):2249143. [Abstract]
- J Nanobiotechnology. 2026 Mar 6;24(1):345. [Abstract]
- Immun Ageing. 2026 Jan 16;23(1):7. [Abstract]
- ACS Appl Mater Interfaces. 2025 Jun 25;17(25):36315-36333. [Abstract]
- Chem Eng J Adv. 2026 Feb 16.
- JCI Insight. 2025 Jan 30;10(5):e184468. [Abstract]
- Eur J Med Chem. 2024 Dec 5:279:116842. [Abstract]
- Life Sci. 2026 Jun 15:395:124396. [Abstract]
- Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Int Immunopharmacol. 2022 Sep:110:109030. [Abstract]
- Med Oncol. 2023 Apr 10;40(5):141. [Abstract]
- Bone. 2024 Nov:188:117222. [Abstract]
- J Orthop Surg Res. 2025 Dec 23;20(1):1079. [Abstract]
- J Dent Sci. 2026 Jan 20.
- J Dent Sci. 2025 Jan;20(1):539-552. [Abstract]
- Int J Parasitol Drugs Drug Resist. 2025 Aug 6:29:100607. [Abstract]
- Appl Biochem Biotechnol. 2024 Oct;196(10):7362-7374. [Abstract]
- bioRxiv. 2026 Mar 29.
- SSRN. 2025 Sep 23.
- bioRxiv. 2025 March 11.
- Dis Markers. 2021 Oct 15;2021:5838582. [Abstract]
- Oxid Med Cell Longev. 2021 Mar 30:2021:6661534. [Abstract]
Customer Validation & Images
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
Histological Imaging/Staining
-
Cell Migration/Invasion Assay
-
Cell Proliferation/Viability Assay
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| BXPC-3 | IC50 |
10 μM
Compound: Zoledronate
|
Cytotoxicity against human BXPC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human BXPC-3 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 33132173] |
| Ca-Ski | IC50 |
10 μM
Compound: Zoledronate
|
Cytotoxicity against human Ca-Ski cells assessed as cell growth inhibition
Cytotoxicity against human Ca-Ski cells assessed as cell growth inhibition
|
[PMID: 33132173] |
| CFPAC-1 | IC50 |
10 μM
Compound: Zoledronate
|
Cytotoxicity against human CFPAC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human CFPAC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 33132173] |
| Erythrocyte | IC50 |
>200 μM
Compound: NBP3
|
Antiparasitic activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 24 hrs followed by [3H]hypoxanthine addition by microbeta scintillation counter analysis
Antiparasitic activity against Plasmodium falciparum 3D7 infected in human erythrocyte assessed as intraerythrocytic growth inhibition incubated for 24 hrs followed by [3H]hypoxanthine addition by microbeta scintillation counter analysis
|
[PMID: 33522236] |
| HCT-116 | IC50 |
61.582 μM
Compound: ZOL
|
Cytotoxicity against FPPS-positive human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against FPPS-positive human HCT116 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 31785819] |
| HeLa | IC50 |
10 μM
Compound: Zoledronate
|
Cytotoxicity against human HeLa cells assessed as cell growth inhibition
Cytotoxicity against human HeLa cells assessed as cell growth inhibition
|
[PMID: 33132173] |
| HFF | IC50 |
0.79 μM
Compound: 3
|
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
In vitro inhibitory concentration against the growth of Toxoplasma gondii in human foreskin fibroblast monolayer cells (HFF cells)
|
[PMID: 15857119] |
| HFF | IC50 |
7.8 μM
Compound: 3
|
Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.60 uM, experiment 1)
Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.60 uM, experiment 1)
|
[PMID: 15857119] |
| HFF | IC50 |
7.8 μM
Compound: 3
|
Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.79 uM, experiment 3)
Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 0.79 uM, experiment 3)
|
[PMID: 15857119] |
| HFF | IC50 |
8.3 μM
Compound: 3
|
Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 1.1 uM, experiment 2)
Inhibitory concentration against the growth of Toxoplasma gondii overexpressing FPPS enzyme in human foreskin fibroblast monolayer cells; (control = 1.1 uM, experiment 2)
|
[PMID: 15857119] |
| HL-60 | IC50 |
595.8 μM
Compound: Zoledronic acid
|
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay
|
[PMID: 24928399] |
| Huh-7 | IC50 |
60 μM
Compound: Zoledronate
|
Cytotoxicity against human HuH7 cells after 144 hrs by MTT assay
Cytotoxicity against human HuH7 cells after 144 hrs by MTT assay
|
[PMID: 24607589] |
| J774 | IC50 |
7.8 μM
Compound: Zoledronate
|
Cytotoxicity against mouse J774 cells assessed as reduction in cell viability
Cytotoxicity against mouse J774 cells assessed as reduction in cell viability
|
[PMID: 24813742] |
| JJN-3 | EC50 |
9.4 μM
Compound: 1
|
Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay
Antiproliferative activity against human JJN-3 after 72 hrs by MTT assay
|
[PMID: 22390415] |
| K562 | EC50 |
>100 μM
Compound: Zoledronate
|
Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 15 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA
Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 15 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA
|
[PMID: 31531198] |
| K562 | EC50 |
23 μM
Compound: Zoledronate
|
Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 240 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA
Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 240 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA
|
[PMID: 31531198] |
| K562 | EC50 |
79 μM
Compound: Zoledronate
|
Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 60 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA
Activation of butyrophilin 3A1 in human K562 cells assessed as interferon-gamma production pretreated for 60 mins followed by HMBPP-treated Vgamma9Vdelta2 T cells addition and measured after 20 hrs by ELISA
|
[PMID: 31531198] |
| KB | ED50 |
63.7 μM
Compound: 67
|
Dose to inhibit the growth of human KB carcinoma cell line
Dose to inhibit the growth of human KB carcinoma cell line
|
[PMID: 16162013] |
| LoVo | IC50 |
34.914 μM
Compound: ZOL
|
Cytotoxicity against FPPS-positive human Lovo cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against FPPS-positive human Lovo cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 31785819] |
| MCF7 | IC50 |
23 μM
Compound: Zoledronic acid
|
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 24928399] |
| MCF7 | IC50 |
27.7 μM
Compound: 2
|
Antiproliferative activity against human MCF7 cell line by MTT assay
Antiproliferative activity against human MCF7 cell line by MTT assay
|
[PMID: 16970405] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: ZOL
|
Cytotoxicity against FPPS-negative human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
Cytotoxicity against FPPS-negative human MDA-MB-231 cells assessed as reduction in cell viability measured after 48 hrs by MTT assay
|
[PMID: 31785819] |
| MIA PaCa-2 | EC50 |
13.4 μM
Compound: 6
|
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human MIAPaCa2 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
|
[PMID: 31725297] |
| NCI-H460 | IC50 |
11.7 μM
Compound: 2
|
Antiproliferative activity against human NCI-H460 cell line by MTT assay
Antiproliferative activity against human NCI-H460 cell line by MTT assay
|
[PMID: 16970405] |
| PANC-1 | EC50 |
16.1 μM
Compound: 6
|
Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
Cytotoxicity against human PANC1 cells assessed as decrease in cell growth measured after 72 hrs by MTT assay
|
[PMID: 31725297] |
| PANC-1 | IC50 |
10 μM
Compound: Zoledronate
|
Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
Cytotoxicity against human PANC-1 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay
|
[PMID: 33132173] |
| RPMI-8226 | EC50 |
11 μM
Compound: 1
|
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay
Cytotoxicity against human RPMI8226 cells after 72 hrs by MTT assay
|
[PMID: 23998921] |
| RPMI-8226 | EC50 |
11 μM
Compound: 1; ZOL
|
Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay
Antiproliferative activity against human RPMI8226 cells after 72 hrs by MTT assay
|
[PMID: 30016091] |
| SF-268 | IC50 |
14.3 μM
Compound: 2
|
Antiproliferative activity against human SF-268 cell line by MTT assay
Antiproliferative activity against human SF-268 cell line by MTT assay
|
[PMID: 16970405] |
| SiHa | IC50 |
10 μM
Compound: Zoledronate
|
Cytotoxicity against human SiHa cells assessed as cell growth inhibition
Cytotoxicity against human SiHa cells assessed as cell growth inhibition
|
[PMID: 33132173] |
| T-cell | EC50 |
5.4 μM
Compound: 4
|
Effective concentration against human Gamma delta T cells
Effective concentration against human Gamma delta T cells
|
[PMID: 15828834] |
| T-cell | IC50 |
170 μM
Compound: 1
|
Activation of human CD4+ Vgamma2/Vdelta2 T cell clone JN.23 assessed as TNF-alpha release after 16 hrs by sandwich ELISA in presence of antigen presenting cell line, CP.EBV
Activation of human CD4+ Vgamma2/Vdelta2 T cell clone JN.23 assessed as TNF-alpha release after 16 hrs by sandwich ELISA in presence of antigen presenting cell line, CP.EBV
|
[PMID: 23610597] |
| Vero | IC50 |
35 μM
Compound: NBP3
|
Antiparasitic activity against Trypanosoma cruzi amastigotes infected in vero cells assessed as parasite growth inhibition incubated for 48 hrs by light microscopy
Antiparasitic activity against Trypanosoma cruzi amastigotes infected in vero cells assessed as parasite growth inhibition incubated for 48 hrs by light microscopy
|
[PMID: 33522236] |
Zoledronic Acid monohydrate (0.1-1 μM; 48 hours) increases receptor activator of nuclear factor kB ligand (RANKL) and sclerostin mRNA expressions in osteocyte-like MLO-Y4 cells[2].
Zoledronic Acid monohydrate increases the expression of osteoclastogenesis supporting factor from MLO-Y4 cells[2].
Zoledronic Acid monohydrate enhances the RANKL expression via IL-6/ JAK2/STAT3 pathway in MLO-Y4 cells[2].
Zoledronic Acid monohydrate inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways[3].
Zoledronic Acid monohydrate (10-100 μM; 1-7 days) markedly reduces the viability of MC3T3-E1 cells[4].
Zoledronic Acid monohydrate (10-100 μM; 1-7 days) induces apoptosis in MC3T3-E1 cells[4].
Zoledronic Acid monohydrate (10-100 μM; 4 days) inhibits cell viability due to the induction of apoptosis[4].
Zoledronic Acid monohydrate exerts inhibitory effects on the differentiation and maturation of MC3T3-E1 cells at concentrations <1 μM[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MC3T3-E1 cells
-
Concentration:0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
-
Incubation Time:1 day, 3 days, 5 days, 7 days
-
Result:Reduced cells viability at 10 µM and 100 µM.
-
Cell Line:MC3T3-E1 cells
-
Concentration:0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
-
Incubation Time:1 days, 4 days, 7 days
-
Result:Increased the number of early apoptotic cells and late apoptotic or necrotic cells at dose-dependent and time-dependent (high concentrations).
-
Cell Line:MC3T3-E1 cells
-
Concentration:0.02 µM , 0.1 µM, 1 µM, 10 µM, 100 µM
-
Incubation Time:4 days
-
Result:Down-regulated the protein level of inactive caspase-3 and up-regulated the protein level of active caspase-3 at the concentrations of 10 and 100 µM.
Zoledronic Acid monohydrate (0.5-1 mg/kg; i.p.; weekly; for 3 weeks) inhibits both osteoclast and osteoblasts function and bone remodeling in vivo interfering with bone mechanical properties[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Five-week-old C57BL6 mice[5]
-
Dosage:0.05 mg/kg, 0.5 mg/kg, 1 mg/kg
-
Administration:Intraperitoneal injection, weekly, for 3 weeks
-
Result:Inhibited both osteoclast and osteoblasts function and bone remodeling at 0.5 mg/kg and 1 mg/kg.
Chemical Information
-
CAS No. 165800-06-6
-
Appearance Solid
-
분자량 290.10
-
화학식 C5H12N2O8P2
-
Color White to off-white
-
SMILES
OC(P(O)(O)=O)(P(O)(O)=O)CN1C=CN=C1.[H]O[H]
-
Synonyms
Zoledronate monohydrate; CGP 42446 monohydrate; CGP42446A monohydrate; ZOL 446 monohydrate
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (26)
-
Journal Impact Factor
-
Most Recent
-
Natl Sci Rev
Chemical engineering of γδ T cells with cancer cell-targeting antibodies for enhanced tumor immunotherapy. [Abstract]2025 Jun 27;12(8):nwaf256. PMID: 40842867 -
Nat Commun
2024 Mar 21;15(1):2529. PMID: 38514612
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 21;15(1):2529. [Abstract]
Representative TRAP staining images of femur cortical bone and quantification of TRAP positive cell number from PBS or zoledronic acid (100 µg/kg, intraperitoneal injection, once per week for 2 weeks) treated 4-week-old Dmp1Cre-DTAki/wt mice.
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Mar 21;15(1):2529. [Abstract]
Representative confocal images of femur cortical bone and quantitative result of TCVs from PBS or zoledronic acid (100 µg/kg, intraperitoneal injection, once per week for 2 weeks) treated 4-week-old Dmp1Cre-DTAki/wt mice.
-
ACS Nano
A Dual-Targeted Metal-Organic Framework Based Nanoplatform for the Treatment of Rheumatoid Arthritis by Restoring the Macrophage Niche. [Abstract]2023 Jul 25;17(14):13917-13937. PMID: 37429012 -
Gut Microbes
Microbial metabolite butyrate promotes anti-PD-1 antitumor efficacy by modulating T cell receptor signaling of cytotoxic CD8 T cell. [Abstract]2023 Dec;15(2):2249143. PMID: 37635362 -
J Nanobiotechnology
Matrix micro/nano-topography drives oncogenic signaling and drug response in a 3D osteosarcoma model. [Abstract]2026 Mar 6;24(1):345. PMID: 41787498 -
Immun Ageing
2026 Jan 16;23(1):7. PMID: 41546035 -
ACS Appl Mater Interfaces
Biomaterial-Based Lymphangiogenesis-Enhanced Therapeutic Strategy for Robustly-Integrated Medication-Related Osteonecrosis of Jaw Prevention. [Abstract]2025 Jun 25;17(25):36315-36333. PMID: 40518597 -
-
JCI Insight
2025 Jan 30;10(5):e184468. PMID: 39883525
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: JCI Insight. 2025 Jan 30;10(5):e184468. [Abstract]
Serum creatinine, urea nitrogen, and uric acid levels in CKD mice or sham-operated mice (Zoledronic Acid: i.p., 20/100 μg/kg, once per day, 4 weeks).
-
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Life Sci
A three-dimensional dynamic in vitro bone remodeling model reveals multicellular effects of anti-osteoporotic agents. [Abstract]2026 Jun 15:395:124396. PMID: 41990913 -
Commun Biol
Mevalonate pathway inhibition reduces bladder cancer metastasis by modulating RhoB protein stability and integrin β1 localization. [Abstract]2024 Nov 9;7(1):1476. PMID: 39521858
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]
Representative images and statistical graph of transwell assays from the indicated groups after treatment with ZOL at different concentrations (0, 10 and 20 μM) in UM-UC-3 cells and T24 cells for 48 h.
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]
An MTT assay was performed to detect changes in the proliferation of BLCA cells (UM-UC-3, T24 and 5637) after treatment with different concentrations (0, 1, 2, 5, 10, 20, 40, 60 and 80 μM) of ZOL for 48 h.
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]
Western blot analyses of EMT-related proteins in ZOL-treated ((0, 10 and 20 μM, 48 h) UM-UC-3, T24 and 5637 cells. GAPDH was used as the loading control.
Zoledronic acid monohydrate purchased from MedChemExpress. Usage Cited in: Commun Biol. 2024 Nov 9;7(1):1476. [Abstract]
ZOL (100 μg/kg, intraperitoneally injection, three times a week for 4 weeks). Representative images of H&E-stained mouse lung tissue sections (n = 3)and statistical analysis of the number of metastatic nodules in H&E-stained mouse lung tissue sections.
-
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Int Immunopharmacol
2022 Sep:110:109030. PMID: 35978519 -
Med Oncol
2023 Apr 10;40(5):141. PMID: 37036615 -
Bone
Zoledronic acid relieves steroid-induced avascular necrosis of femoral head via inhibiting FOXD3 mediated ANXA2 transcriptional activation. [Abstract]2024 Nov:188:117222. PMID: 39102974 -
J Orthop Surg Res
Localized therapeutic strategy based on microRNA-21-loaded mesoporous silica nanoparticles hydrogel improves bone repair in medication-related osteonecrosis of the jaw. [Abstract]2025 Dec 23;20(1):1079. PMID: 41437101 -
-
J Dent Sci
Beta-adrenergic receptor antagonist propranolol prevents bisphosphonate-related osteonecrosis of the jaw by promoting osteogenesis. [Abstract]2025 Jan;20(1):539-552. PMID: 39873080 -
Int J Parasitol Drugs Drug Resist
Promising efficacy of nitrogen-containing bisphosphonates against the infection of Cryptosporidium spp. [Abstract]2025 Aug 6:29:100607. PMID: 40782657 -
Appl Biochem Biotechnol
Zoledronic Acid Accelerates ER Stress-Mediated Inflammation by Increasing PDE4B Expression in Bisphosphonate-Related Osteonecrosis of the Jaw. [Abstract]2024 Oct;196(10):7362-7374. PMID: 38523176 -
-
-
-
Dis Markers
Study on the Killing Effect of γδ T Cells Activated by Rukangyin on Breast Cancer MDA-MB-231 Cells. [Abstract]2021 Oct 15;2021:5838582. PMID: 34691287 -
Oxid Med Cell Longev
Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis. [Abstract]2021 Mar 30:2021:6661534. PMID: 33859780
용액&용해도
H2O : 28.57 mg/mL (98.48 mM; ultrasonic and adjust pH to 9 with 1 M NaOH)
H2O : 14.29 mg/mL (49.26 mM; ultrasonic and adjust pH to 8 with NaOH)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 3.33 mg/mL (11.48 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
순도&문서
-
Data Sheet (287 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lianwei Wang, et al. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review. BMC Cancer. 2020; 20: 1059. [Content Brief]
[2]. Hyung Joon Kim, et al. Zoledronate Enhances Osteocyte-Mediated Osteoclast Differentiation by IL-6/RANKL Axis. Int J Mol Sci. 2019 Mar; 20(6): 1467. [Content Brief]
[3]. Xiao-Lin Huang, et al. Zoledronic acid inhibits osteoclast differentiation and function through the regulation of NF-κB and JNK signalling pathways. Int J Mol Med. 2019 Aug;44(2):582-592. [Content Brief]
[4]. XIN HUANG, et al. Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. 2016 Jan; 13(1): 613-622. [Content Brief]
[5]. Samantha Pozzi, et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15;15(18):5829-39. [Content Brief]
[6]. Shea GKH, et al. Oral Zoledronic acid bisphosphonate for the treatment of chronic low back pain with associated Modic changes: A pilot randomized controlled trial. J Orthop Res. 2022 Feb 23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / H2O | 1 mM | 3.4471 mL | 17.2354 mL | 34.4709 mL | 86.1772 mL |
| 5 mM | 0.6894 mL | 3.4471 mL | 6.8942 mL | 17.2354 mL | |
| 10 mM | 0.3447 mL | 1.7235 mL | 3.4471 mL | 8.6177 mL | |
| 15 mM | 0.2298 mL | 1.1490 mL | 2.2981 mL | 5.7451 mL | |
| 20 mM | 0.1724 mL | 0.8618 mL | 1.7235 mL | 4.3089 mL | |
| 25 mM | 0.1379 mL | 0.6894 mL | 1.3788 mL | 3.4471 mL | |
| 30 mM | 0.1149 mL | 0.5745 mL | 1.1490 mL | 2.8726 mL | |
| 40 mM | 0.0862 mL | 0.4309 mL | 0.8618 mL | 2.1544 mL | |
| H2O | 50 mM | 0.0689 mL | 0.3447 mL | 0.6894 mL | 1.7235 mL |
| 60 mM | 0.0575 mL | 0.2873 mL | 0.5745 mL | 1.4363 mL | |
| 80 mM | 0.0431 mL | 0.2154 mL | 0.4309 mL | 1.0772 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Zoledronic acid monohydrate Related Classifications
HY-13777A Related Classifications
Powered by Bioz